Does IPILIMUMAB Cause Immune-mediated enterocolitis? 988 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 988 reports of Immune-mediated enterocolitis have been filed in association with IPILIMUMAB (YERVOY). This represents 2.7% of all adverse event reports for IPILIMUMAB.
988
Reports of Immune-mediated enterocolitis with IPILIMUMAB
2.7%
of all IPILIMUMAB reports
73
Deaths
504
Hospitalizations
How Dangerous Is Immune-mediated enterocolitis From IPILIMUMAB?
Of the 988 reports, 73 (7.4%) resulted in death, 504 (51.0%) required hospitalization, and 86 (8.7%) were considered life-threatening.
Is Immune-mediated enterocolitis Listed in the Official Label?
Yes, Immune-mediated enterocolitis is listed as a known adverse reaction in the official FDA drug label for IPILIMUMAB.
What Other Side Effects Does IPILIMUMAB Cause?
Death (3,710)
Malignant neoplasm progression (3,296)
Diarrhoea (2,557)
Off label use (2,097)
Colitis (1,988)
Pyrexia (1,796)
Rash (1,556)
Fatigue (1,447)
Intentional product use issue (1,329)
Nausea (1,169)
What Other Drugs Cause Immune-mediated enterocolitis?
NIVOLUMAB (1,289)
PEMBROLIZUMAB (858)
CARBOPLATIN (307)
PACLITAXEL (188)
DURVALUMAB (165)
ATEZOLIZUMAB (156)
LENVATINIB (143)
PEMETREXED (129)
BEVACIZUMAB (92)
TREMELIMUMAB\TREMELIMUMAB-ACTL (63)
Which IPILIMUMAB Alternatives Have Lower Immune-mediated enterocolitis Risk?
IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE
IPILIMUMAB vs IPRATROPIUM
IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS
IPILIMUMAB vs IPTACOPAN
IPILIMUMAB vs IRBESARTAN